GI Dynamics picks contract manufacturing partner

GI Dynamics picks contract manufacturing partner

Proven Process Medical Devices will be the contract manufacturing partner for GI Dynamic’s EndoBarrier product.

Subscribe
Contract Manufacturing Devices/Implants/Equipment

Boston, Massachusetts & Sydney, Australia – Medical device company GI Dynamics Inc., who commercialized EndoBarrier in Europe, the Middle East, and South America for patients with type 2 diabetes and obesity – selected Proven Process Medical Devices Inc. (PPMD) as its contract manufacturing partner.

PPMD, designer and manufacturer of Class II and Class III medical devices, was founded in 1994 to address the unmet need for an outsource provider to the medical device industry with the in-depth technical, quality, and regulatory knowledge needed to develop and manufacture sophisticated medical products. Company founders developed a proven process that combines state-of-the-art research and development with design, process, and quality controls for new product development and manufacturing success.

PPMD was selected for its experience in the medical device field and ability to support production of implantable medical device technology. Manufacturing of EndoBarrier will take place at its facilities in Mansfield, Massachusetts,

“We are pleased to be selected by GI Dynamics for the manufacture of EndoBarrier,” says Ken Fine, president and co-founder of PPMD. “We look forward to continuing our relationship with GI Dynamics to provide this important product for the treatment of type 2 diabetes and obesity.”

“We look forward to working with PPMD as our manufacturing partner,” says Scott Schorer, president and CEO of GI Dynamics. “We have been working towards the transfer of our manufacturing to PPMD for the past 18 months, and expect that PPMD will manufacture EndoBarrier to the highest quality and in a tightly cost-contained manner.”

“The implementation of our contract manufacturing partnership is another critical action as we move to make EndoBarrier available around the world for patients suffering from type 2 diabetes and obesity," Schorer notes.